- Hyphens Pharma International (SGX:1J5)'s 1H24 revenue was up 33.4% y-o-y to S$99.6m, driven by robust sales across all key segments.
- Gross profit increased by 24.2% y-o-y in line with the growth in revenue, with gross profit margin decreasing from 37.5% in 1H2023 to 34.9% in 1H2024.
- - Read this at SGinvestors.io -
Business Highlights
- Hyphens Pharma recently secured regulatory approvals for several new products in its Specialty Pharma segment. These products include Wynzora, Amenalief and Ustefav (Ustekinumab biosimilar). These approvals will enable Hyphens Pharma to expand its offerings across new and existing markets in the future, enhancing not only the company’s portfolio but also provides a strong foundation for long-term growth.
- - Read this at SGinvestors.io -
- For the Medical Hypermart and Digital segment, Hyphens Pharma continues to invest in the digital space, reflecting its strategic pivot towards digital sales channels to meet evolving customer behaviors.
Earnings forecast revision
- Read more at SGinvestors.io.
Daniel Ng Ming Ci SAC Capital Research | Matthias Chan SAC Capital | https://www.saccapital.com.sg/ 2024-08-22
Previous report by SAC:
2024-05-16 Hyphens Pharma International - Robust Growth Across All Segments In 1Q24.
Price targets by 2 other brokers at Hyphens Pharma Target Prices.
Listing of research reports at Hyphens Pharma Analyst Reports.
Relevant links:
Hyphens Pharma Share Price History,
Hyphens Pharma Announcements,
Hyphens Pharma Dividends & Corporate Actions,
Hyphens Pharma News Articles
